indiana fishing license
golden empire jili slot game
Asian spot liquefied natural gas (LNG) prices gained this week, the first rise after three weekly declines, as the imminent expiry of a transit deal for Russian gas through Ukraine to Europe lent support to prices. The average LNG price for February delivery into north-east Asia (LNG-AS) was $14.10 per million British thermal units (mmBtu), up 6% from $13.30/mmBtu last week, industry sources estimated. Asian LNG prices have gained 20% this year and averaged $11.97/mmBtu in 2024. “The biggest thing people are keeping an eye on is TTF’s upward movement,” said Masanori Odaka, senior analyst at Rystad Energy, referring to the Dutch Title Transfer Facility (TTF) hub. He added that some industry participants were taking the expiry of a Russia-Ukraine gas transit contract at the end of this year as bullish news. Russian gas supply into Europe could affect prices on the TTF, which also has an impact on Asia LNG prices. Russian President Vladimir Putin said on Thursday there was no time left this year to sign a new Ukrainian gas transit deal, and blamed Ukraine for refusing to extend the agreement that also brings gas to Slovakia, the Czech Republic and Austria. “The other thing is a cold front potential in the U.S. which could end in a deep freeze like it did in 2021,” Rystad’s Odaka added. “Asia seems relatively well stocked, so below average to normal winter will not likely cause China, Korea or Japan to buy significant volumes in the spot market.” In Europe, delivered prices turned higher this week, mostly on continued uncertainty about the agreement to continue gas transit to Europe through Ukraine after the current deal expires, said Martin Senior, head of LNG pricing at commodity pricing agency Argus. “Weak wind generation forecasts in northwest Europe during the Christmas break and into the weekend also supported gas-fired generation demand,” he added. S&P Global Commodity Insights assessed its daily North West Europe LNG Marker (NWM) price benchmark for cargoes delivered in February on an ex-ship (DES) basis at $13.76/mmBtu on Dec. 24, a $0.20/mmBtu discount to the February gas price at the Dutch TTF hub. Argus assessed the price at $13.745/mmBtu, while Spark Commodities assessed the price for January delivery at $13.753/mmBtu. The U.S. arbitrage to Northeast Asia via the Cape of Good Hope for January is still currently closed due to the recent TTF rally, providing more incentive for U.S. cargos to deliver to Northwest Europe instead, said Spark Commodities analyst Qasim Afghan. In LNG freight, Atlantic rates held steady at $23,500/day, while Pacific rates fell to $21,500/day, added Afghan. Source: ReutersChargers more worried about the cold than the opponent, thrash Pats and secure playoffsHappy New Year 2025 Celebration: Not everyone celebrates New Year on January 1. Here's list of regions and religions with different dates for new years
Jimmy Carter, nation’s 39th president who became influential human rights advocate, diesUnlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For , the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said , who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight - up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients - as many as 1 in 5 - may not respond well to the medications. It’s a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It’s all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight - and a person’s response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for , who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn’t happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It’s not game over,” Dushay said. Trying a different version of the new class of drugs may help. , who didn’t respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I’m hoping it’s slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” Copyright © 2024 The Washington Times, LLC. Click to Read More and View Comments Click to Hide
Formula 1 star who called Michael Schumacher 'blind or stupid' snubbed Ferrari moveNvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the past five years and becoming the most valuable company in the world for a brief period (it's currently No. 2). However, Nvidia is far from the only opportunity in the AI or semiconductor space. In fact, one chipmaker just reported 400%-plus year-over-year data center revenue growth and overall revenue growth of 84% to $8.7 billion in its latest earnings report (for the quarter ending Nov. 28). I'm talking about Micron Technology ( MU 3.48% ) , the memory-chip specialist that is surprisingly down 44% from its recent peak, despite that blowout growth. That discount and its potential in AI make the stock an appealing buy right now. Let's review the company's recent results first and then get into the buy case. What is Micron? Micron is a leader in memory chips, including DRAM, NAND, and high bandwidth memory (HBM). The company is also an integrated device manufacturer, meaning it both designs and manufactures its own chips like Intel and Samsung do. Memory chips are a highly cyclical business, prone to price fluctuations and industry gluts, and owning its own foundries makes Micron more exposed to the boom and bust cycle in semiconductors. Running foundries requires a high level of capital, but the integrated business model allows the company to better capture margins when the business is performing well. The chart below, which shows Micron's price compared to its previous high, gives a sense of how volatile the stock has been. As you can see, over the last decade, the stock has fallen by 40% or more on four occasions before hitting a new all-time high. Data by YCharts. Cyclicality and volatility are part of the risk in investing in Micron, but there's no question the semiconductor sector is in a boom right now, driven by the explosive growth of AI, though some subsectors like PCs and smartphones are weaker. In addition to Nvidia's blowout growth, industry bellwether Taiwan Semiconductor Manufacturing recently reported revenue growth of 36% in the third quarter to $23.5 billion, showing strong growth in the sector. Noting strong AI demand, management said that data center revenue topped 50% of total revenue for the first time in the quarter, following a trail first blazed by Nvidia in the chip sector. That now makes the vast majority of Micron's revenue from the data center, where AI computing is taking place. Why Micron stock tumbled on the report After reporting fiscal first-quarter earnings on Wednesday, Micron stock plunged as much as 19% on Thursday on its weak second-quarter guidance. However, the company has a history of being conservative with its guidance, and the weakness was due to consumer markets like smartphones, whereas the AI business remains strong. HBM, the part of the business closely tied to AI, is seeing impressive growth. The company said it's on track to achieve its HBM target for the fiscal year and reach a "substantial record" in HBM revenue, including "significantly improved profitability, and free cash flow" in the fiscal year. Micron expects a sequential decline in revenue and adjusted earnings per share (EPS) in the second quarter, falling from $8.7 billion to $7.9 billion and for adjusted EPS to slip from $1.79 to $1.43. However, management's explanation for the weak outlook should reassure investors. CEO Sanjay Mehrotra said the company had warned previously that seasonality and customer inventory reductions in consumer-facing segments like smartphones would affect Q2 results. He added, "We are now seeing a more pronounced impact of customer inventory reductions," and continued, "We expect this adjustment period to be relatively brief and anticipate customer inventories reaching healthier levels by spring, enabling stronger bit shipments in the second half of fiscal and calendar 2025." In other words, the issues causing the weak second-quarter guidance look like just a speed bump for the company rather than a sustained headwind, and management expects to return to sequential growth in the second half of the year. For a stock to fall 17% on a one-time guidance cut feels like a misread by the market and a buying opportunity for investors. Why Micron is a no-brainer buy A sell-off driven by short-term news often presents a good buying opportunity, but there's more to Micron's buy case than that. Micron is clearly capitalizing on the AI boom with the surge in data center revenue, and with its largest customer, which is believed to be Nvidia, now making up 13% of its revenue. A close relationship with Nvidia is clearly a tailwind at this stage of the AI boom as Nvidia just reported 94% growth in year-over-year revenue in its Q3 report. Micron's results are notoriously lumpy and cyclical, but it has the ability to generate huge profits under the right circumstances -- and those seem to be shaping up as the AI boom plays out. For example, Micron expects the addressable market for HBM to jump from $16 billion in 2024 to $64 billion in 2028 and to $100 billion in 2030. Even if it just maintains its market share in that segment, its HBM revenue will be up 4x in four years and 6x and six years. Finally, Micron stock is also much cheaper than its AI and chip stock peers, trading at a forward P/E of just 10 based on this year's estimates. While those estimates are likely to come down after its guidance, Micron still looks like a bargain at any price near that. Micron investors should monitor the chip and AI cycle closely, but there's a lot of upside potential in the stock. Getting back to its peak this summer would mean a 75% jump for the stock, and shares could continue to rally further over the next year or two, especially if it continues to see strong growth in the data center. Micron is the rare AI stock that offers rapid growth and a good value right now.Every car discontinued in Australia in 2024
Asian Stocks Eye Cautious Gains as US Worries Ease: Markets Wrap
Letter To The Year 202449ers' Kyle Shanahan confident Nick Sorensen will grow as a coachadidas AG ( OTCMKTS:ADDYY – Get Free Report ) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 7,500 shares, a decrease of 20.2% from the November 30th total of 9,400 shares. Based on an average trading volume of 76,600 shares, the short-interest ratio is currently 0.1 days. Analysts Set New Price Targets Several analysts recently weighed in on the stock. HSBC downgraded shares of adidas from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Barclays reaffirmed an “equal weight” rating on shares of adidas in a report on Monday, September 9th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”. Get Our Latest Report on ADDYY adidas Stock Performance adidas ( OTCMKTS:ADDYY – Get Free Report ) last announced its earnings results on Tuesday, October 29th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. adidas had a net margin of 1.91% and a return on equity of 7.93%. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $7.01 billion. On average, equities research analysts predict that adidas will post 2.15 EPS for the current year. Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in ADDYY. GAMMA Investing LLC lifted its position in adidas by 29.4% in the third quarter. GAMMA Investing LLC now owns 792 shares of the company’s stock worth $105,000 after purchasing an additional 180 shares during the period. Capital Square LLC acquired a new position in shares of adidas during the 2nd quarter valued at $1,616,000. Finally, Hantz Financial Services Inc. bought a new stake in shares of adidas in the 2nd quarter worth $4,809,000. adidas Company Profile ( Get Free Report ) adidas AG, together with its subsidiaries, designs, develops, produces, and markets athletic and sports lifestyle products in Europe, the Middle East, Africa, North America, Greater China, the Asia-Pacific, and Latin America. It offers footwear, apparel, and accessories and gear, such as bags and balls under the adidas brand; golf footwear and apparel under the adidas Golf brand; and outdoor footwear under the Five Ten brand. Read More Receive News & Ratings for adidas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for adidas and related companies with MarketBeat.com's FREE daily email newsletter .
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scientology Expands Its Impact In Santo André, The Industrial Heart Of São Paulo
Medical devices companies in the country are of the view that investments and job opportunities will spearhead the growth of this sector. As one of the fastest growing within the healthcare ecosystem, valued at $15.35 billion in 2023, and expected to grow over $20 billion by 2029, India can be the fourth largest Asian medical devices market after Japan, China, and South Korea. Arvind Vaishnav, head, Philips Innovation Campus and Innovation Partnerships--Growth region, Philips, said "The emphasis on automation across healthcare is likely to increase globally. There is a concerted effort towards addressing staff shortages and relieving staff of repetitive tasks and processes. We are already witnessing this with generative AI functioning as a virtual assistant, organizing clinical notes and simplifying ways patient information is communicated across teams. It is also now apparent that AI will be adopted beyond automation. It is proven that AI can help simplify complex diagnostics, enabling less experienced professionals to provide high-quality care with confidence. Imagine, AI embedded in ultrasound systems. It allows physicians to detect, diagnose and monitor cardiac conditions more confidently and efficiently. From a technology perspective, new technologies for minimally invasive procedures are becoming more advanced. This implies the need for physicians to collect and analyze data from a wide range of sources, such as live X-ray images, 3D ultrasound, intravascular ultrasound (IVUS), to name a few all the while closely monitoring the patient. Hence, integration of systems, software and devices will become increasingly important, he added. In 2025, technology trends in healthcare will transition towards managing health outside of the hospital. Advances in technology solutions is expected to support remote detection of patient health risks based on vital signs and other data, said Vaishnav. According to Hariharan Subramanian, managing director, Siemens Healthcare, "India is on track to become a global leader in medical device manufacturing. By scaling up domestic production of high-quality medical equipment, the country will reduce its reliance on imports, achieve self-sufficiency, and stimulate economic growth. Fuelled by rising demand, there is a boost to local production of high-quality devices, and the integration of digital and AI technologies. Moreover, a renewed emphasis on research and development is driving innovation, resulting in safer, more sustainable, and accessible healthcare solutions. With a growing export market on the horizon, the MedTech sector is expected to create significant employment opportunities, nurturing a new generation of experts who will spearhead India's future healthcare innovations, he added. “We have built a strong infrastructure that promotes collaborative innovation, encourages open research and development, and drives manufacturing excellence. Our Innovation Hub, currently under construction in Bengaluru, will set standards for the workplace of the future. The new campus aims to intensify collaboration and creativity, coupled with environmentally friendly, sustainable, energy-efficient solutions. An investment of almost Euro 200 million makes it the largest site of Siemens Healthineers globally in terms of built-up area”, said Subramanian. Himanshu Baid, managing director, Poly Medicure, said, "India's med-tech sector is writing a new chapter in global healthcare innovation. The focus on domestic manufacturing, skill development, and healthcare infrastructure has laid the groundwork for India to emerge as a leader in cutting-edge med-tech solutions.” To build on this momentum, it is imperative for companies to step up their investments in R&D and innovation. The future belongs to those who can develop transformative technologies that address the healthcare needs of a dynamic and diverse world. By addressing key supply chain challenges and fostering a culture of innovation, India is poised to set new benchmarks in global healthcare, creating a legacy of excellence and better health outcomes for all, said Baid.
- Previous: golden empire jili png
- Next: golden empire jili slot